Dovitinib (TKI-258, CHIR-258)

製品コードS1018

Dovitinib (TKI-258, CHIR-258)化学構造

分子量(MW):392.43

Dovitinib (TKI258, CHIR258)は一種の多ターゲットRTK阻害剤で、無細胞試験でIII型(FLT3/c-Kit)に作用する効果が一番強くて、このIC50値が1 nM/2 nMです。同時に、Dovitinib (TKI258, CHIR258)はIV型(FGFR1/3)とV型(VEGFR1-4) RTKsにも有効に作用して、IC50値が8-13 nMになりますが、InsR、EGFR、c-Met、EphA2、Tie2、IGF-1RとHER2に作用する効果が少し弱くなります。臨床4期。

サイズ 価格 在庫  
JPY 27516.10 あり
JPY 24477.96 あり
JPY 38876.76 あり
JPY 67674.36 あり

カスタマーフィードバック(7)

  • In vitro assays on CUX1-FGFR1-expressing Ba/F3 cells. a. IL-3 deprivation of Ba/F3 cells transduced with CUX1-FGFR1 resulted in transformation to growth factor independent growth. The mean growth ±SEM of three separate measurements over four consecutive days is presented. b. The dose-response curves of CUX1-FGFR1-transduced Ba/F3 cells, treated with TKI258 and PKC412 for 48 hours in the absence or presence of IL-3 (2 ng/ml) are presented. Points represent the average results of two experiments done in triplicate plotted with the curve-fitting GraphPad Prism 5 software; bars, SD. The calculated IC50 for each inhibitor is indicated. c. Western blot analyses of CUX1-FGFR1-transformed Ba/F3 cells after treatment with PKC412 and TKI258. Phosphorylation of CUX1-FGFR1 and its downstream effectors STAT5 and RPS6K decreased with increasing inhibitor concentrations. Expression of total CUX1-FGFR1, STAT5 and RPS6K remained unaffected. d. Effect of PKC412 and TKI258 on apoptosis of CUX1-FGFR1-expressing Ba/F3 cells after treatment for 48 hours. The percentage of apoptotic plus necrotic CUX1-FGFR1-transduced Ba/F3 cells is indicated.

    haematologica 2011 96, 922-926. Dovitinib (TKI-258, CHIR-258) purchased from Selleck.

    RT112 cells were exposed to PD173074 (PD) (500 nM) for 0-24 h, TKI-258 (TK) (500 nM) or SU5402 (SU) (5 nM) for 1 h. Cells were lysed, FGFR3 was immunoprecipitated (immunoprecipitated, IP) and blots (immunoblot, IB) were probed for phospho-tyrosine and reprobed for FGFR3 or probed for phospho-ERK and reprobed for total ERK.

    Brit J Cancer 2010 104, 75-82. Dovitinib (TKI-258, CHIR-258) purchased from Selleck.

  • Cells were exposed to PD173074 or TKI-258 (500 nM) for 24 h. Cell cycle profile was analysed using the Guava Easycyte Plus flow cytometry system.

    Brit J Cancer 2010 104, 75-82. Dovitinib (TKI-258, CHIR-258) purchased from Selleck.

     

    Orthotopic xenografts of HNSCC cell lines (A) SCC-1 and (B) OSC-19 were treated with dovitinib (20 mg/kg/day). In addition, the OSC-19 xenografts were treated with +/ radiation therapy. Marker, mean for triplicate; bars, SE. Statistical significance by unpaired t-test, p < 0.05.

    Oral Oncol 2012 48, 1242-9. Dovitinib (TKI-258, CHIR-258) purchased from Selleck.

  • Treatments were initiated at time of orthotopic implantation. Growth stabilization was seen by day 8 of treatment (Fig. B). On day 17, tumors were har-vested and histological analysis was performed (Fig. C). Following Ki67 staining, tumors from control xenografts were found to have a higher percentage of proliferating cells (62%) compared to those treated with dovitinib (14%; p = 0.005). The incidence of lymph nodes metastasis was greater in the control cohort ( n = 15) com-pared to those treated with dovitinib (n = 5).

    Oral Oncol 2012 48, 1242-9. Dovitinib (TKI-258, CHIR-258) purchased from Selleck.

    Dose–response curves for HNSCC cells and fibroblasts treated in vitro with dovitinib (0–1000 nM). Boxes, mean for triplicate; bars, SE

    Oral Oncol 2012 48, 1242-9. Dovitinib (TKI-258, CHIR-258) purchased from Selleck.

  • Ba/F3 cell lines expressing the recombinant TEL/kinase domain fusion protein for FGFR1-4 .Cells were grown in RPMI 1640 containing 10% FBS and 500 ng/mL puromycin. The parental Ba/F3 cell line transduced with an empty vector was grown in 10 ng/mL IL-3 (R & D systems). Cell viability was assessed at 72 hours using the Cell Titer 96 Aqueous One Solution (Promega). Data were plotted as percent viability relative to vehicle-treated cells and are shown as mean (±SD) from 3 experiments.

    AACR 2011 Dovitinib (TKI-258, CHIR-258) purchased from Selleck.

製品安全説明書

FLT3阻害剤の選択性比較

生物活性

製品説明 Dovitinib (TKI258, CHIR258)は一種の多ターゲットRTK阻害剤で、無細胞試験でIII型(FLT3/c-Kit)に作用する効果が一番強くて、このIC50値が1 nM/2 nMです。同時に、Dovitinib (TKI258, CHIR258)はIV型(FGFR1/3)とV型(VEGFR1-4) RTKsにも有効に作用して、IC50値が8-13 nMになりますが、InsR、EGFR、c-Met、EphA2、Tie2、IGF-1RとHER2に作用する効果が少し弱くなります。臨床4期。
ターゲット
FLT3 [1]
(Cell-free assay)
c-Kit [1]
(Cell-free assay)
FGFR1 [1]
(Cell-free assay)
VEGFR3/FLT4 [1]
(Cell-free assay)
FGFR3 [1]
(Cell-free assay)
1 nM 2 nM 8 nM 8 nM 9 nM
体外試験

Dovitinib potently inhibits the FGF-stimulated growth of WT and F384L-FGFR3-expressing B9 cells with IC50 of 25 nM. In addition, Dovitinib inhibits proliferation of B9 cells expressing each of the various activated mutants of FGFR3. Interestingly, there are minimal observed differences in the sensitivity of the different FGFR3 mutations to Dovitinib, with the IC50 ranging from 70 to 90 nM for each of the various mutations. IL-6-dependent B9 cells containing vector only (B9-MINV cells are resistant to the inhibitory activity of Dovitinib at concentrations up to 1 μM. Dovitinib inhibits cell proliferation of KMS11 (FGFR3-Y373C), OPM2 (FGFR3-K650E), and KMS18 (FGFR3-G384D) cells with IC50 of 90 nM (KMS11 and OPM2) and 550 nM, respectively. Dovitinib inhibits FGF-mediated ERK1/2 phosphorylation and induces cytotoxicity in FGFR3-expressing primary MM cells. BMSCs does confer a modest degree of resistance with 44.6% growth inhibition for cells treated with 500 nM Dovitinib and cultured on stroma compared with 71.6% growth inhibition for cells grown without BMSCs. Dovitinib inhibits proliferation of M-NFS-60, an M-CSF growth-driven mouse myeloblastic cell line with a median effective concentration (EC50) of 220 nM. [1] Treatment of SK-HEP1 cells with Dovitinib results in a dose-dependent reduction in cell number and G2/M phase arrest with reduction in the G0/G1 and S phases, inhibition of anchorage-independent growth and blockage of bFGF-induced cell motility. The IC50 for Dovitinib in SK-HEP1 cells is approximately 1.7 μM. Dovitinib also significantly reduces the basal phosphorylation levels of FGFR-1, FGFR substrate 2α (FRS2-α) and ERK1/2 but not Akt in both SK-HEP1 and 21-0208 cells. In 21-0208 HCC cells, Dovitinib significantly inhibits bFGF-induced phosphorylation of FGFR-1, FRS2-α, ERK1/2 but not Akt. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SupB15 Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwNES5JO69VQ>? MoDXNlUzODJyN{O=
SupB15-R NYXtd4tHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4ryXGlEPTB;MD61OVgh|ryP M4TIdVI2OjB{MEez
BaF3-pSRα M{Xkfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3uyNGlEPTB;MD62Olgh|ryP NYXic5JbOjV{MEKwO|M>
BaF3-p210Bcr-Abl NITKRWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnFepZKSzVyPUCuOlkzKM7:TR?= NUTi[pBSOjV{MEKwO|M>
BaF3-p210Bcr-Abl-T315I NXGyUGFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXe4e2dSUUN3ME2yMlYzPiEQvF2= NGHPS|gzPTJyMkC3Ny=>
CCRF-CEM MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDxXINKSzVyPUCuN|k5KM7:TR?= MYeyOVIxOjB5Mh?=
CEM/C2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nGUWlEPTB;MT6xNlUh|ryP MoXJNlUzODJyN{K=
Nalm-6 NWKzTmEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWS3WotIUUN3ME2wMlM5OiEQvF2= M13yfFI2OjB{MEey
SEM-K2 MlTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fROGlEPTB;MD6wNlIh|ryP NV\EeIF6OjV{MEKwO|I>
HB-1119 NETn[otIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD5WXBTUUN3ME2wMlAzQCEQvF2= NF\QRpczPTJyMkC3Ni=>
RS4:11 MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVH5Tnl3UUN3ME2yMlgyKM7:TR?= NFzzSJMzPTJyMkC3Ni=>
Nalm-6 MlS2RZBweHSxc3nzJGF{e2G7 NWrrNWdyOiEQvF2= M1nCOFI1NzR6IHi= MnnLbY5lfWOnczDhdI9xfG:|aYOgdoV{fWy2aX7nJIlvKGGkb4X0JFczLSCxZjDj[YxtKGSnYYToJIFnfGW{IEK0JIghfHKnYYTt[Y51KGGwZDC4NUUh[W[2ZYKgOFghcA>? M4nldVI2OjB{MEey
SEM-K2 MY\BdI9xfG:|aYOgRZN{[Xl? M1XaO|AvOS9zIN88US=> NH\iN5UzPCCq MVHpcoR2[2W|IHXhdox6KGGyb4D0c5NqeyCxZjDTSW0uUzJiY3XscJMh[XRiMD6xJO69VSCjZoTldkAzPCCq M3HZdVI2OjB{MEey
HCT-116 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi4bGhKSzVyPUOuNFUxNjV6IN88US=> NVz1bFQ6OjR2OUW3OVA>
HT-29 NULPXWw6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jnRmlEPTB;NT6yNU46OyEQvF2= NF7ubZczPDR7NUe1NC=>
SW-480 M2fK[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTQTWM2OD12LkOzNE41PyEQvF2= NX3zeWpoOjR2OUW3OVA>
CaCO2 NHnCd49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTNwMkOwMlY1KM7:TR?= NYL5N4hCOjR2OUW3OVA>
LS174T NUTRSJlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoruTWM2OD12LkOzNE41PyEQvF2= MXKyOFQ6PTd3MB?=
HEC-1A NH\pUIRHfW6ldHnvckBCe3OjeR?= MU[wMlA2NzBwMT:wMlUh|ryP NFXrXoY4OiCq MlTOZ4F2e2W|IHGg[IVkemWjc3WgbY4hW1SDVEOsJGVTUyxiYX7kJGFMXCCyaH;zdIhwenmuYYTpc44> MoW3NlQ1QTV5NUC=
AN3CA M{TEPGZ2dmO2aX;uJGF{e2G7 MkDTNE4xPS9yLkGvNE42KM7:TR?= M3:1[lczKGh? NYLvd3ZO[2G3c3XzJIEh\GWlcnXhd4UhcW5iU2TBWFMtKEWUSzygZY5lKEGNVDDwbI9{eGixconsZZRqd25? MX[yOFQ6PTd3MB?=
MFE-296  MUfGeY5kfGmxbjDBd5NigQ>? NFLNd4IxNjB3L{CuNU8xNjVizszN M3OyXVczKGh? NXLN[HVG[2G3c3XzJIEh\GWlcnXhd4UhcW5iU2TBWFMtKEWUSzygZY5lKEGNVDDwbI9{eGixconsZZRqd25? M1nYfVI1PDl3N{Ww
UMC3 MVLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mo\5NU0yOCEQvF2= MYm3NkBp MkTYbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M2LEUVI1OzJ3NE[x
5637 NULCU29zS2WubDDWbYFjcWyrdImgRZN{[Xl? MmHBNU0yOCEQvF2= MlLGO|IhcA>? NU\WfFd1cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MXSyOFMzPTR4MR?=
HU456 M3jISWNmdGxiVnnhZoltcXS7IFHzd4F6 MmXjNU0yOCEQvF2= MmLtO|IhcA>? MlPhbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M{S1SVI1OzJ3NE[x
MGHU4 NWTIcotMS2WubDDWbYFjcWyrdImgRZN{[Xl? NFz1e5gyNTFyIN88US=> NITwUHQ4OiCq MXHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NWPHdoUyOjR|MkW0OlE>
HT1376 M{LrTGNmdGxiVnnhZoltcXS7IFHzd4F6 M17XXlEuOTBizszN NWHDV4JXPzJiaB?= NF[xUmhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M3vhRVI1OzJ3NE[x
RT112 NI\KXYNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NF3aclAyNTFyIN88US=> NVy3UmpbPzJiaB?= MWLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NYfZflJqOjR|MkW0OlE>
T24 M3PWTWNmdGxiVnnhZoltcXS7IFHzd4F6 NHrxSXUyNTFyIN88US=> MVG3NkBp NEP5R3pqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MoTFNlQ{OjV2NkG=
BFTC905 M4GyemNmdGxiVnnhZoltcXS7IFHzd4F6 NWLUOpZCOS1zMDFOwG0> MUO3NkBp NVrVUmdicW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NWi2dotZOjR|MkW0OlE>
TCC-SUP NFHpW2NE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHPiPYcyNTFyIN88US=> MkDrO|IhcA>? NF;rW5BqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NV3pVYZ7OjR|MkW0OlE>
RT4 NIn4XWxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MV2xMVExKM7:TR?= NHfubYE4OiCq M4\ZXYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MWCyOFMzPTR4MR?=
HONE1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zt[lAvOS1zMDFOwG0> M1H3OFQ5yqCq NIryZ2xqdmS3Y3XzJGczN01iZHXsZZkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NEfiT4gzPDJ|OEC5OC=>
HNE1 NWjqe3BrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzGZnoxNjFvMUCg{txO NF3oWVM1QMLiaB?= NVrvPHNGcW6mdXPld{BIOi:PIHTlcIF6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MXWyOFI{QDB7NB?=
CNE2  MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkC5NE4yNTFyIN88US=> M4LWbVQ5yqCq Mn\abY5lfWOnczDHNk9OKGSnbHH5JIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXy M4XX[lI1OjN6MEm0
C666-1 NU\sSnBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTxfppFOC5zLUGwJO69VQ>? MkL2OFjDqGh? NV\k[ZJScW6mdXPld{BIOi:PIHTlcIF6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NI\BS3UzPDJ|OEC5OC=>
HeLa MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHmNE4yNTFyIN88US=> M3G0c|I1KGh? NUPQSlF4cW6mdXPld{BIOi:PIHHydoV{fCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NWS2Z291OjR{M{iwPVQ>
Hep3B NXjTW2VET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DINlAvOS1zMDFOwG0> NVzjZpNmOjRiaB?= NVzUdWNrcW6mdXPld{BIOsLiYYLy[ZN1yqB? NXfGcpNPOjR{M{iwPVQ>
HepG2 NXXZ[pVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV60PEBp MmXBTWM2OD1{LkeyO{DDuSByLkSyPUDPxE1? MX2yN|U1PjV7MR?=
Hep3B NV3HOms2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\TOFghcA>? NUjLS45VUUN3ME20MlIzOyEEsTCwMlg{QSEQvF2= MkPkNlM2PDZ3OUG=
PLC/PRF5 NYPMTJRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zLNFQ5KGh? NH7WfmNKSzVyPUG2MlEzOCEEsTC0MlAxOSEQvF2= MmTkNlM2PDZ3OUG=
Huh7 NUXKWHFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHFeY81QCCq NXGyNZpNUUN3ME2xOU4xODdiwsGgO{4{OzRizszN Mm[3NlM2PDZ3OUG=
HepG2 NVnJUXNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDIO|IhcA>? MnnqTWM2OD1zLkKwNEDDuSByLkKyOkDPxE1? NU\EbGlNOjN3NE[1PVE>
Hep3B Mm\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUe3NkBp MYfJR|UxRTBwOEmyJOKyKDBwMES0JO69VQ>? M33CNlI{PTR4NUmx
PLC/PRF5 M3;GTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXu3NkBp M2GzWWlEPTB;Mz6xNVAhyrFiMD6zN|ch|ryP NWHtOVJzOjN3NE[1PVE>
Huh7 M{O2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7lO|IhcA>? NIDWOFFKSzVyPUOuPVgxKMLzIECuPFA{KM7:TR?= NXS2UYYyOjN3NE[1PVE>
MFE280 NIHsO|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPIT4pKSzVyPUCuOFIhyrFiMD6wOkDPxE1? M{P1W|I{PDR|OEC1
AN3CA NUj3T3JtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrIO5dEUUN3ME2wMlUxKMLzIECuNVAh|ryP NInmXIszOzR2M{iwOS=>
HEC155 NFHyT|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\vR2tKSzVyPUCuOlYhyrFiMD6wPUDPxE1? Mn\QNlM1PDN6MEW=
MFE296 NUPpVVRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwNk[gxtEhOC5zOTFOwG0> NXzzdI5YOjN2NEO4NFU>
SPAC1S M4rObGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\RTWM2OD1yLke3JOKyKDBwMEig{txO MVeyN|Q1OzhyNR?=
RL952 NV34[YI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwOUOgxtEhOC5yMTFOwG0> MXmyN|Q1OzhyNR?=
EN1 M3Hu[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXZcndKSzVyPUGuNFIhyrFiMD6yOUDPxE1? Mn3FNlM1PDN6MEW=
SNGII MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrP[VFMUUN3ME2xMlI1KMLzIECuNlgh|ryP Mo[zNlM1PDN6MEW=
ISHIKAWA Mk\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\PRWlEPTB;MT6zNEDDuSByLkGxJO69VQ>? M4H4OFI{PDR|OEC1
HEC1A MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFS2TVlKSzVyPUGuN|QhyrFiMD6zNEDPxE1? NVXnZWE4OjN2NEO4NFU>
KLE NHX5T2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjLO3hKSzVyPUGuN|chyrFiMD6wNkDPxE1? NIf0UmEzOzR2M{iwOS=>
SNGM MmfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDCOnBkUUN3ME2xMlQzKMLzIECuNVMh|ryP M3q5XVI{PDR|OEC1
USPC2 NHjiSlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTFwNkKgxtEhOC5yMTFOwG0> MViyN|Q1OzhyNR?=
EN NWnT[HBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnYTWM2OD1zLk[2JOKyKDBwMEGg{txO NHnkSYkzOzR2M{iwOS=>
MFE319 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDvTWM2OD1zLki3JOKyKDBwNEWg{txO MoDHNlM1PDN6MEW=
EFE184 NWHYNYtbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2D2dWlEPTB;Mj6wOEDDuSByLkGzJO69VQ>? NVG5UJFCOjN2NEO4NFU>
ECC1 NHriNIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTJwMEegxtEhOC5yMTFOwG0> MlXCNlM1PDN6MEW=
HEC1B NY\r[3U4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTJwNUegxtEhOC5{MzFOwG0> MUWyN|Q1OzhyNR?=
USPC1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PxRmlEPTB;Mj62NEDDuSByLkGzJO69VQ>? MmjaNlM1PDN6MEW=
SPAC1L NICzSZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1i3RmlEPTB;Mz6wOkDDuSBzLkG0JO69VQ>? NXriTJpqOjN2NEO4NFU>
HUVEC MVzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3LiTlAuOjVizszN NVHu[HlNPzJiaB?= NEnBRXBFVVOR M2LQT4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MmX2NlMzOjhyMUe=
HMVEC NH7jTldE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MViwMVI2KM7:TR?= M4P2WVczKGh? Mk\1SG1UVw>? M4e2XolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NFXmVnAzOzJ{OECxOy=>
MHCC-97H NFuzXopE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MXKwMVI2KM7:TR?= M4T3elczKGh? MlT1SG1UVw>? NU\UXXNjcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NWrVdlhTOjN{MkiwNVc>
SMMC7721 NVT0SZRoS2WubDDWbYFjcWyrdImgRZN{[Xl? NIDKcm0xNTJ3IN88US=> M3jZS|czKGh? M1KxdWROW09? NHHlbmJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M4niPFI{OjJ6MEG3
Huh-7 M{jVUWFxd3C2b4Ppd{BCe3OjeR?= NFu1cHgxNTF{LkWg{txO NVrkR4xrOjRiaB?= M2\PeWROW00EoB?= M132eJNmdnOrdHn6[ZMhUEOFIHPlcIx{KHSxIGTSRWlNNSCjbnSgeIlo[XS3eoXtZYIucW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MVqyNlI{ODR5OR?=
Sk-Hep1 NHu5PHlCeG:ydH;zbZMhSXO|YYm= M4jyPVAuOTJwNTFOwG0> NYnpVmpvOjRiaB?= MmXSSG1UV8Li M3nJOpNmdnOrdHn6[ZMhUEOFIHPlcIx{KHSxIGTSRWlNNSCjbnSgeIlo[XS3eoXtZYIucW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M{jzR|IzOjNyNEe5
Hep3B Ml64RZBweHSxc3nzJGF{e2G7 NI\oOZoxNTF{LkWg{txO NIrtToMzPCCq MXnEUXNQyqB? NYPNem57e2Wwc3n0bZpmeyCKQ1OgZ4VtdHNidH:gWHJCUUxvIHHu[EB1cWejdIX6eY1i[i2rbnT1Z4VlKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NI[zNJQzOjJ|MES3PS=>
PLC5 M1f1T2Fxd3C2b4Ppd{BCe3OjeR?= M1P4XlAuOTJwNTFOwG0> MoX4NlQhcA>? Ml:5SG1UV8Li NYWyeIJoe2Wwc3n0bZpmeyCKQ1OgZ4VtdHNidH:gWHJCUUxvIHHu[EB1cWejdIX6eY1i[i2rbnT1Z4VlKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mln0NlIzOzB2N{m=
PLC5 MVLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFXwcnUxNTF3IN88US=> M3jWVVczKGh? MlL0doVlfWOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5mesLi NXTRWI1kOjJzOECzNFg>
Hep3B MXjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3nsO|AuOTVizszN NYf5Zmo4PzJiaB?= NHPOZXZz\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{wrC= M1HVXlIzOThyM{C4
Sk-Hep1 NVPNfoVOS2WubDDWbYFjcWyrdImgRZN{[Xl? M36wXFAuOTVizszN MWS3NkBp M2T1c5Jm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XMEoB?= M1nONVIzOThyM{C4
Huh-7 MVLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MkGyNE0yPSEQvF2= NInpWW84OiCq M1OwUJJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XMEoB?= MnfiNlIyQDB|MEi=
PLC5 MXvBdI9xfG:|aYOgRZN{[Xl? MXGwMVE2KM7:TR?= MoHsNlQhcA>? NVziSINncW6lcnXhd4V{KGGyb4D0c5Rq[yClZXzsJIRm[XSqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{wrC= MX2yNlE5ODNyOB?=
Hep3B NV3CUIFjSXCxcITvd4l{KEG|c3H5 MmfZNE0yPSEQvF2= M3zTUFI1KGh? MUHpcoNz\WG|ZYOgZZBweHSxdHnjJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? NFPwXIEzOjF6MEOwPC=>
Sk-Hep1 M4TWN2Fxd3C2b4Ppd{BCe3OjeR?= NVPUNYJvOC1zNTFOwG0> M{[0ZVI1KGh? MVvpcoNz\WG|ZYOgZZBweHSxdHnjJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? NIXtNHczOjF6MEOwPC=>
Huh-7 MnqxRZBweHSxc3nzJGF{e2G7 NHfQUJUxNTF3IN88US=> MXKyOEBp M4LZ[4lv[3KnYYPld{BieG:ydH;0bYMh[2WubDDk[YF1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5mesLi Mn7PNlIyQDB|MEi=
PLC5 MYLGeY5kfGmxbjDBd5NigQ>? NInRd5QxNTFyIN88US=> M4rORlI1KGh? NXfid2dP[2G3c3XzJIRwe2VvZHXw[Y5l\W62IFTORUBnemGpbXXueIF1cW:w MUWyNlE5ODNyOB?=
Hep3B MUHGeY5kfGmxbjDBd5NigQ>? MonUNE0yOCEQvF2= Mo\tNlQhcA>? NFTMc5Vk[XW|ZYOg[I9{\S2mZYDlcoRmdnRiRF7BJIZz[WevZX70ZZRqd25? MlX1NlIyQDB|MEi=
Sk-Hep1 MUTGeY5kfGmxbjDBd5NigQ>? M{DiVFAuOTBizszN NYHnclhGOjRiaB?= MnL2Z4F2e2W|IHTvd4Uu\GWyZX7k[Y51KESQQTDmdoFodWWwdHH0bY9v Mmr1NlIyQDB|MEi=
Huh-7 M2nXc2Z2dmO2aX;uJGF{e2G7 MlfDNE0yOCEQvF2= MVKyOEBp MnPEZ4F2e2W|IHTvd4Uu\GWyZX7k[Y51KESQQTDmdoFodWWwdHH0bY9v M{\zSVIzOThyM{C4
SW780 NGLiT4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPnOUBl NUnNWYFjUUN3ME21NEBvVQ>? NXLCZ3FiOjFzMUm2OlE>
RT112 NW\sToV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVe1JIQ> M2XyO2lEPTB;MUWgcm0> M163SlIyOTF7Nk[x
RT4 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDrTVA2KGR? M3rhT2lEPTB;NTDuUS=> NWjxZW1SOjFzMUm2OlE>
JMSU1 MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;hOUBl NWDRbJFPUUN3ME21NEBvVQ>? Mk\XNlEyOTl4NkG=
J82 MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nUXlUh\A>? M1HzOGlEPTB;MUSwNEBvVQ>? M2DMTFIyOTF7Nk[x
97-7 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrHdJc2KGR? NU[wZ|ZZUUN3ME2xNFAxKG6P NFHh[IMzOTFzOU[2NS=>
RT112 Mo\NSpVv[3Srb36gRZN{[Xl? NUTMcWhuPTByIH7N MnXwNlQhcA>? MonlbY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJINmdGy|IHnuJGcyyqCjY3PvcZBidmmnZDDifUBiKGSnY4LlZZNmKGmwIGOgZY5lKEd{L12gdIhie2W| M{LEWlIyOTF7Nk[x
RT4 Mof2SpVv[3Srb36gRZN{[Xl? M1v5elUxOCCwTR?= MYWyOEBp M3jkUolv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBk\WyuczDpckBIOcLiYXPjc41x[W6rZXSgZpkh[SCmZXPy[YF{\SCrbjDTJIFv\CCJMj;NJJBp[XOncx?= NGjhfJozOTFzOU[2NS=>
MGH-U3 MmDISpVv[3Srb36gRZN{[Xl? NILRO5A2ODBibl2= M2HENlI1KGh? NF2yXm9qdmO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[2WubIOgbY4hTzIEoHHjZ49ueGGwaXXkJIJ6KGFiZHXjdoVie2ViaX6gV{BidmRiR{KvUUBxcGG|ZYO= MmO0NlEyOTl4NkG=
SW780 MV7GeY5kfGmxbjDBd5NigQ>? M37TRVUxOCCwTR?= MX:yOEBp MmnKbY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJINmdGy|IHnuJGcyyqCjY3PvcZBidmmnZDDifUBiKGSnY4LlZZNmKGmwIGOgZY5lKEd{L12gdIhie2W| NVjKTJNwOjFzMUm2OlE>
97-7 M1v3WGZ2dmO2aX;uJGF{e2G7 MVq1NFAhdk1? MXqyOEBp MkjZbY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJINmdGy|IHnuJGcyyqCjY3PvcZBidmmnZDDifUBiKGSnY4LlZZNmKGmwIGOgZY5lKEd{L12gdIhie2W| NHHLN|YzOTFzOU[2NS=>
 J807C M1Kw[GNmdGxiVnnhZoltcXS7IFHzd4F6 NUD2dmVvOC12MECgcm0> MVG0PEBp M2fSUolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MWOxOVU6QDhzNB?=
Y373C MmjTR4VtdCCYaXHibYxqfHliQYPzZZk> NGe0TZQxNTRyMDDuUS=> NEK4UHY1QCCq NUi1OZFKcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MkHPNVU2QTh6MUS=
K650E NX;LXGRNS2WubDDWbYFjcWyrdImgRZN{[Xl? MlT0NE01ODBibl2= M3fjcVQ5KGh? MVfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NFjUSJgyPTV7OEixOC=>
G384D NWDR[XBqS2WubDDWbYFjcWyrdImgRZN{[Xl? M1P2blAuPDByIH7N NFLvbnQ1QCCq MYLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NYTDZVBoOTV3OUi4NVQ>
F384L MYXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{PjUFAuPDByIH7N MXy0PEBp MnPubY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M{n6[VE2PTl6OEG0
KMS11 MnjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWm3NkBp NH7HdW1KSzVyPUmwJI5O MoTiNVU2QTh6MUS=
KMS18 NUftVWhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXS3NkBp MYnJR|UxRTV3MDDuUS=> MU[xOVU6QDhzNB?=
OPM2 NFLLSW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYG3NkBp NETxRVZKSzVyPUmwJI5O NEXZZmsyPTV7OEixOC=>
H929 NXXVXod{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjrXlI6PzJiaB?= M2X0bGlEPTB-IEK1NFAhdk1? Mny0NVU2QTh6MUS=
8226 NVr4OZl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYi3NkBp MmTFTWM2OD5iMkWwNEBvVQ>? M1XyPFE2PTl6OEG0
U266 NYPlOpp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYm3NFNSPzJiaB?= NF;0SWNKSzVyPjCyOVAxKG6P NGfpZVQyPTV7OEixOC=>

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Dovitinib induces both cytostatic and cytotoxic responses in vivo resulting in regression of FGFR3-expressing tumors.[1] Dovitinib shows a dose- and exposure-dependent inhibition of target receptor tyrosine kinases (RTKs) expressed in tumor xenografts. Dovitinib potently inhibits tumor growth of six HCC lines. Inhibition of angiogenesis correlated with inactivation of FGFR/PDGFRβ/VEGFR2 signaling pathways. In an orthotopic model, Dovitinib potently inhibits primary tumor growth and lung metastasis and significantly prolonged mouse survival. [2] Administration of Dovitinib results in significant tumor growth inhibition and tumor regressions, including large, established tumors (500-1,000 mm3). [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

In vitro kinase assays:

The inhibitory concentration of 50% (IC50) values for the inhibition of RTKs by Dovitinib are determined in a time-resolved fluorescence (TRF) or radioactive format, measuring the inhibition by Dovitinib of phosphate transfer to a substrate by the respective enzyme. The kinase domains of FGFR3, FGFR1, PDGFRβ, and VEGFR1-3 are assayed in 50 mM HEPES (N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid), pH 7.0, 2 mM MgCl2, 10 mM MnCl2 1 mM NaF, 1 mM dithiothreitol (DTT), 1 mg/mL bovine serum albumin (BSA), 0.25 μM biotinylated peptide substrate (GGGGQDGKDYIVLPI), and 1 to 30 μM adenosine triphosphate (ATP) depending on the Km for the respective enzyme. ATP concentrations are at or just below Km. For c-KIT and FLT3 reactions the pH is raised to 7.5 with 0.2 to 8 μM ATP in the presence of 0.25 to 1 μM biotinylated peptide substrate (GGLFDDPSYVNVQNL). Reactions are incubated at room temperature for 1 to 4 hours and the phosphorylated peptide captured on streptavidin-coated microtiter plates containing stop reaction buffer (25 mM EDTA [ethylenediaminetetraacetic acid], 50 mM HEPES, pH 7.5). Phosphorylated peptide is measured with the DELFIA TRF system using a Europium-labeled antiphosphotyrosine antibody PT66. The concentration of Dovitinib for IC50 is calculated using nonlinear regression with XL-Fit data analysis software version 4.1 (IDBS). Inhibition of colony-stimulating factor-1 receptor (CSF-1R), PDGFRα, insulin receptor (InsR), and insulin-like growth factor receptor 1 (IGFR1) kinase activity is determined at ATP concentrations close the Km for ATP.
細胞試験: [1]
+ 展開
  • 細胞株: B9 cells, MM cell lines
  • 濃度: 100 nM
  • 反応時間: 48-96 hours
  • 実験の流れ: Cell viability is assessed by 3-(4,5-dimethylthiazol)-2,5-diphenyl tetrazolium (MTT) dye absorbance. Cells are seeded in 96-well plates at a density of 5 × 103 (B9 cells) or 2 × 104 (MM cell lines) cells per well. Cells are incubated with 30 ng/mL aFGF and 100 μg/mL heparin or 1% IL-6 where indicated and increasing concentrations of Dovitinib. For each concentration of Dovitinib, 10 μL aliquots of drug or DMSO diluted in culture medium is added. For drug combination studies, cells are incubated with 0.5 μM dexamethasone, 100 nM Dovitinib, or both simultaneously where indicated. To evaluate the effect of Dovitinib on growth of MM cells adherent to BMSCs, 104 KMS11 cells are cultured on BMSC-coated 96-well plates in the presence or absence of Dovitinib. Plates are incubated for 48 to 96 hours. For assessment of macrophage colony-stimulating factor (M-CSF)-mediated growth, 5 × 103 M-NFS-60 cells/well are incubated with serial dilutions of Dovitinib with 10 ng/mL M-CSF and without granulocyte-macrophage colony-stimulating factor (GM-CSF). After 72 hours cell viability is determined using Cell Titer-Glo Assay. Each experimental condition is performed in triplicate.
    (参考用のみ)
動物試験:[1]
+ 展開
  • 動物モデル: 8-week-old female BNX mice bearing KMS11 cells
  • 製剤: 5 mM citrate buffer
  • 投薬量: 10, 30, or 60 mg/kg
  • 投与方法: Gavage
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 30 mg/mL (76.44 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 392.43
化学式

C21H21FN6O

CAS No. 405169-16-6
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01497392 Completed Adenocarcinoma of the Pancreas|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific Roswell Park Cancer Institute|National Cancer Institute (NCI)|Novartis March 29, 2012 Phase 1
NCT02048943 Withdrawn Duct Cell Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific Roswell Park Cancer Institute|National Cancer Institute (NCI)|Novartis March 2015 Phase 1
NCT02268435 Withdrawn Gastrointestinal Stromal Tumors Asan Medical Center March 2015 Phase 1
NCT02108782 Withdrawn Gastrinoma|Glucagonoma|Insulinoma|Pancreatic Polypeptide Tumor|Recurrent Islet Cell Carcinoma|Somatostatinoma Academic and Community Cancer Research United|National Cancer Institute (NCI) October 2014 Phase 2
NCT02116803 Completed Solid Tumors Novartis Pharmaceuticals|Novartis May 2014 Phase 2|Phase 3
NCT01994590 Active, not recruiting Prostate Cancer M.D. Anderson Cancer Center|Novartis May 2014 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

FLT3信号経路図

FLT3 Inhibitors with Unique Features

相関FLT3製品

Tags: Dovitinib (TKI-258, CHIR-258)を買う | Dovitinib (TKI-258, CHIR-258) ic50 | Dovitinib (TKI-258, CHIR-258)供給者 | Dovitinib (TKI-258, CHIR-258)を購入する | Dovitinib (TKI-258, CHIR-258)費用 | Dovitinib (TKI-258, CHIR-258)生産者 | オーダーDovitinib (TKI-258, CHIR-258) | Dovitinib (TKI-258, CHIR-258)化学構造 | Dovitinib (TKI-258, CHIR-258)分子量 | Dovitinib (TKI-258, CHIR-258)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID